WillItSurvive
Pharma and healthcare groups · India

Granules India

granulesindia.com ↗

Indian generic drugmaker making APIs and finished formulations, mostly for the US market.

Defensible for now
Assessed 26 July 2026 · Evidence as of 26 July 2026
Real protection, with named pressure against it.
On the recordSince 26 July 2026 · Checkable from date not yet announced, expected H2 2026 · Every call on the record Checkpoint: FDA re-inspection of the Gagillapur plant, which is blocking nine pending US approvals
The call

Granules keeps growing on commodity APIs and a complex-generics pivot, but nine US product approvals sit frozen until Gagillapur clears FDA re-inspection.

Granules India makes generic medications and sells them to the US and other markets. The company has real advantages: it has gotten 103 FDA approvals for its drugs, and it makes the actual pills in factories that competitors cannot easily replicate or replace. However, the US FDA issued a serious warning letter in February 2025 about its main factory in Gagillapur, which has frozen 9 new drug approvals and could block sales if not fixed quickly. The one thing that changes everything is whether the FDA inspection at that factory passes in 2026. If it does, the company stays on track; if it fails, the company faces a crisis.

Why
01
AI pressure: None apparent. AI drug-discovery tools target new molecules, not off-patent generics Granules makes; little direct effect either way. Could AI do the core job? Unlikely.
02
Bigger players: Sun Pharma, Aurobindo Pharma, Teva, Sandoz. Bigger generic and API makers chase the same commodity molecules, like paracetamol and metformin, pressuring prices Granules can charge. Could a giant copy it? Probably.
03
What protects it. Its own FDA-approved ANDA filings, two First-to-File exclusivities, and roughly 30% of world paracetamol supply keep volume sticky.
What would change this call
FDA re-inspection of Gagillapur facility occurs and outcome is published. Shows whether the 9 frozen US approvals unfreeze or the compliance overhang worsens.
Ascelis Peptides/CDMO reports quarterly PAT status ahead of FY27 target. Shows whether the CDMO pivot is closing losses or continuing to bleed cash.
Q2 FY27 results (Oct-Nov 2026) show North America revenue share and margin trend. Shows whether US pricing pressure or tariffs are compressing margins.
Key numbers
  • Q1 FY27 PAT up 60% YoY to ₹1,800 million (2026-06-30)
  • North America made up 72-79% of quarterly revenue (2026-03-31)
  • Complex generics rose from 31% to 43% of dosage revenue (2026-03-31)
Named risks
  • Gagillapur facility remains under FDA Warning Letter since Feb 2025, blocking 9 US product approvals. Severity: high
  • Heavy North America revenue concentration (72-79%) exposes Granules to US generic pricing or tariff shocks. Severity: medium
  • Ascelis CDMO/peptide unit still loss-making, with FY2027 breakeven target unproven. Severity: medium
  • Late entry into CDMO/peptides versus faster-growing rivals Laurus Labs and Piramal Pharma. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Aurobindo PharmacontestingCompetes directly in commodity API/generics; no exclusive barriers, as of FY26 reporting
Sun PharmaceuticalcontestingLarger incumbent in same generics/API space, cited as comparison in market data feeds, 2024
Laurus Labslosing toAnalyst coverage projects Laurus's CDMO segment growing 35-40% YoY vs Granules' smaller, newer CDMO base, Jan 2025 report
Piramal Pharmalosing toCited by analysts as outgrowing Granules' nascent peptide/CDMO unit, per Jan 2025 broker note
Alkermes (LUMRYZ)gaining onGranules secured sole First-to-File status for generic LUMRYZ, targeting Alkermes' branded drug, July 2026
Questions people ask
Is Granules India profitable in 2026?
Yes. Granules India reported FY2025-26 (year ended March 2026) consolidated PAT of ₹5,950 million, up 19% YoY, on revenue of ₹53,656 million (up 20% YoY) and a 65.0% gross margin, per its July 2026 earnings summary.
What is Granules India's biggest current risk?
An unresolved FDA Warning Letter issued February 26, 2025 for its flagship Gagillapur facility, citing CGMP violations, which is blocking nine pending US product approvals until re-inspection occurs; no re-inspection date was set as of July 2026.
Who owns Granules India?
Granules India is publicly listed on the BSE and NSE. Promoter family (led by Dr. Krishna Prasad Chigurupati) held 38.02% as of June 2026, down from 41-42% in FY2022, with FIIs at 17.5% and DIIs at 16.1%.
Can AI replace Granules India's manufacturing business?
No. Granules relies on physical, regulated manufacturing (10 plants, 39 billion finished-dosage units/year) and 153 global regulatory filings with 103 approvals. It is deploying agentic AI internally for quality/deviation monitoring, per a July 2026 interview, but this is a tool, not displacement.
Who is Granules India's biggest competitor?
Granules competes with commodity API and generics makers Sun Pharmaceutical, Aurobindo Pharma, Teva, and Sandoz, plus Indian CDMO/generics peers Laurus Labs, Divi's Laboratories, Piramal Pharma, and Natco Pharma, none of which structurally bar Granules from the market.
Is Granules India's new peptide CDMO business (Ascelis) working?
Not yet profitable. Ascelis Peptides/Senn Chemicals generated ₹1,593 million in FY26 revenue but posted a roughly ₹24.8 crore EBITDA loss in Q3 FY26; the company targets annual PAT-positivity for the unit in FY2027.
Timeline
  • 2026-07-21Q1 FY27 results: revenue ₹14,768 million, PAT up 60% YoY to ₹1,800 million
  • 2026-07-06Secured sole First-to-File ANDA status for generic LUMRYZ (sodium oxybate ER)
  • 2026-04-29Q4 FY26 results: revenue ₹14,706 million, up 23% YoY
  • 2026-03-31FY2025-26 closed: revenue ₹53,656 million, PAT ₹5,950 million, gross margin 65.0%
  • 2025-04-10Closed acquisition of Swiss peptide CDMO Senn Chemicals AG for ~₹192 crore
  • 2025-02-26FDA issued Warning Letter (OAI status) for Gagillapur facility
  • 2025-02Agreed to acquire Senn Chemicals AG, entering peptide CDMO space
  • 2024-09FDA inspection at Gagillapur cited CGMP violations including contamination and pest issues
Revision history
26 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBoston ScientificBecton Dickinson
More in Pharma and healthcare groups →
Sources